Rep. Robert J. Wittman

Maddy summaryThis bill requires public utilities to use the most efficient and high-capacity power line conductors available when building new transmission lines or making major upgrades to existing lines under federal jurisdiction. It creates a legal presumption that costs for these "best-available" conductors will be approved in rate cases, while costs for less efficient conductors will likely be denied. The rule applies only to projects overseen by the Federal Energy Regulatory Commission (FERC). FERC must issue specific rules within 180 days to define what qualifies as a "best-available" conductor based on capacity, efficiency, and thermal performance.

Maddy summaryHR 6213, the Heat Workforce Standards Act of 2025, prohibits the U.S. Department of Labor from finalizing, implementing, or enforcing OSHA's proposed "Heat Injury and Illness Prevention" standard (published August 30, 2024). This bill directly blocks the specific regulatory proposal targeting heat safety in both outdoor and indoor work settings. It does not create new requirements or affect workers; it solely prevents the implementation of the existing OSHA proposal. The bill is procedural, focusing on halting a regulatory action rather than establishing new policy.

Maddy summaryThe AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.

Maddy summaryThis bill establishes the INCLUDE Project at the National Institutes of Health (NIH) to advance research on Down syndrome and related health conditions. It requires NIH to fund high-risk studies on trisomy 21, support inclusive clinical trials for people with Down syndrome across all ages, and investigate co-occurring conditions like Alzheimer’s disease and autoimmunity. The law mandates NIH coordination across its institutes, consultation with patient advocates, and biennial reports to Congress detailing funded research and its real-world applications. The project directly affects individuals with Down syndrome, their families, and medical researchers, aiming to improve diagnosis, treatment, and quality of life through targeted scientific efforts.

Maddy summaryHR 1266, the Combating Illicit Xylazine Act, adds xylazine - a veterinary sedative increasingly found in illicit drug mixtures - to Schedule III of the Controlled Substances Act, regulating its use and trafficking. It directly affects veterinarians, animal owners, and manufacturers by allowing xylazine to be legally dispensed for animal use under specific veterinary prescriptions, while prohibiting non-veterinary human use. The bill includes transition periods (60 days for practitioners, 1 year for labeling) to ease compliance for manufacturers and practitioners, and requires the DEA and FDA to expedite necessary applications. It also mandates two congressional reports on xylazine's illicit use and trafficking patterns, and directs the Sentencing Commission to review penalties for offenses involving xylazine.

Maddy summaryThe Essential Caregivers Act of 2026 requires nursing homes, long-term care hospitals, rehabilitation facilities, and intermediate care facilities to allow two chosen family members or friends to visit residents during times when regular visitation is suspended. These essential caregivers must agree to follow the facility's existing safety and infection control rules, which are no more restrictive than those applied to staff. While facilities can limit access for the first seven days of a suspension or deny entry if a caregiver shows symptoms of a serious infectious disease, they cannot block visits for end-of-life care. Additionally, the bill mandates that complaints about denied access to essential caregivers be investigated and resolved within three days.

Maddy summaryThis bill requires Medicare Advantage plans to implement electronic pre-approval systems for medical services by 2028 and meet transparency reporting standards starting in 2027. Plans must publicly report data on approval/denial rates, appeal outcomes, response times, and technology use for pre-approval requests, including details on how denials relate to clinical criteria. It establishes a 24-hour response timeframe for certain requests and mandates annual reviews of pre-approval requirements based on data and input from seniors and providers. The law directly affects Medicare Advantage plans, seniors enrolled in these plans, and healthcare providers who submit pre-approval requests. These changes aim to make the pre-approval process faster, more transparent, and more accountable for seniors seeking covered medical services.

Maddy summaryHR 3108, the RPM Access Act, increases Medicare reimbursement for remote patient monitoring (RPM) in rural areas by setting a minimum reimbursement floor of 100% for practice expenses and malpractice costs starting in 2026. It requires that RPM services include real-time physician availability to address health issues, use data systems compatible with electronic health records, and mandates providers to report data on cost savings and adherence to medications. The bill directly affects rural Medicare beneficiaries with chronic conditions like heart failure and diabetes, as well as healthcare providers delivering RPM services in underserved rural communities. It also requires a 5-year report to Congress analyzing cost savings from RPM use, including reduced hospitalizations and medication adherence. The law aims to improve access to RPM in rural areas where healthcare shortages are most severe.

Maddy summaryThe Expedited Access to Biosimilars Act modifies federal regulations to streamline the approval process for biosimilar drugs, which are lower-cost versions of existing biologic medicines. The bill requires manufacturers to conduct specific studies on how the drug behaves in the body and how the immune system reacts to it, while limiting the need for additional large-scale clinical trials unless the FDA explicitly determines they are necessary. To ensure transparency, the law mandates that the FDA must provide written notice to drug sponsors within 60 days regarding whether extra studies are required. These changes aim to reduce the time and cost involved in bringing biosimilars to market, potentially increasing patient access to affordable treatment options.

Maddy summaryHR 5549, the Efficient Nuclear Licensing Hearings Act, streamlines the licensing process for nuclear facilities by reducing mandatory hearings. It allows the Nuclear Regulatory Commission (NRC) to issue construction permits, operating licenses, or amendments without a hearing if it provides 30 days' notice and Federal Register publication, skipping the hearing requirement only when an amendment involves "no significant hazards." This change applies to all pending NRC applications after enactment, shifting from current rules requiring hearings unless waived. The bill directly affects nuclear facility developers, the NRC, and communities potentially impacted by licensing decisions through its revised notice and hearing procedures.